Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.

Abstract

BACKGROUND:

Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L-asparaginase (L-ASP) has not been studied.

HYPOTHESIS/OBJECTIVES:

To evaluate the safety and efficacy of L-ASP given concurrently with RAB in dogs with relapsed multicentric lymphoma.

ANIMALS:

Fifty-two dogs with relapse of lymphoma after treatment with at least 1 doxorubicin-based chemotherapy protocol.

METHODS:

Open-label, multicenter, prospective single-arm clinical trial. Dogs were treated with RAB at 1.0 mg/kg IV every 21 days for up to a total of 5 doses. L-asparaginase was administered at 400 IU/kg SQ concurrently with the first 2 treatments of RAB.

RESULTS:

The overall response rate (ORR) for all dogs was 67%, with 19 dogs (41%) achieving a complete response (CR). The median progression-free survival time (MPFS) was 63 days (range 5-428 days). Dogs experiencing a CR as their best response had an MPFS of 144 days (range 44-428 days). Adverse events were similar to previous studies evaluating single agent RAB. Failure to achieve a CR and having previously received L-ASP were negative prognostic factors on multivariate analysis.

CONCLUSIONS AND CLINICAL IMPORTANCE:

Concurrent RAB/L-ASP appears to be both efficacious and safe for treating relapsed multicentric lymphoma in dogs. Adverse events were most often mild and no unexpected toxicoses were observed.

• Authors: Jacob R Cawley, Zachary M Wright, Karri Meleo, Gerald S Post, Craig A Clifford, Kathryn R Vickery, David M Vail, Philip J Bergman, Douglas H Thamm
• Journal: Journal of veterinary internal medicine (J Vet Intern Med) Vol. 34 Issue 2 Pg. 882-889 (Mar 2020) ISSN: 1939-1676 [Electronic] United States
• PMID: 32064697 (Publication Type: Journal Article)
• Copyright: © 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

Chemical References

• Antineoplastic Agents
• Purines
• rabacfosadine
• Asparaginase
• Alanine

Topics

• Alanine (administration & dosage, analogs & derivatives, therapeutic use)
• Animals
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols
• Asparaginase (administration & dosage, therapeutic use)
• Colorado
• Disease-Free Survival
• Dog Diseases (drug therapy)
• Dogs
• Female
• Lymphoma (drug therapy, mortality, veterinary)
• Male
• Neoplasm Recurrence, Local (drug therapy, veterinary)
• Prospective Studies
• Purines (administration & dosage, therapeutic use)
• Remission Induction
• Washington
• Wisconsin